BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25408659)

  • 1. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report.
    Meyer A; Carvalho BJ; Medeiros KA; Pipek LZ; Nascimento FS; Suzuki MO; Munhoz JV; Iuamoto LR; Carneiro-D'Alburquerque LA; Andraus W
    World J Clin Cases; 2021 May; 9(14):3418-3423. PubMed ID: 34002153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure.
    Hahn S; Ayav A; Lopez A
    Case Rep Gastroenterol; 2017; 11(2):422-427. PubMed ID: 29033758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
    J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
    Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M
    Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
    Hartlapp I; Müller J; Kenn W; Steger U; Isbert C; Scheurlen M; Germer CT; Einsele H; Kunzmann V
    Onkologie; 2013; 36(3):123-5. PubMed ID: 23486001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report.
    Ariake K; Motoi F; Mizuma M; Murakami K; Takadate T; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Nakagawa K; Sakata N; Morikawa T; Maeda S; Naitoh T; Egawa S; Unno M
    Surg Case Rep; 2017 Dec; 3(1):15. PubMed ID: 28101795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
    Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
    Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
    Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
    J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review.
    Kobayashi Y; Maeda S; Hama N; Miyamoto A; Uemura M; Miyake M; Nishikawa K; Hirao M; Kato T; Sekimoto M; Mori K; Mano M; Nakamori S
    Int Cancer Conf J; 2018 Jan; 7(1):20-25. PubMed ID: 31149507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis.
    Damm M; Efremov L; Birnbach B; Terrero G; Kleeff J; Mikolajczyk R; Rosendahl J; Michl P; Krug S
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
    Zhang Y; Hochster H; Stein S; Lacy J
    Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness and resource utilization of
    Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
    Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for pancreatic cancer.
    Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
    Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.